<DOC>
	<DOC>NCT00245960</DOC>
	<brief_summary>To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.</brief_summary>
	<brief_title>Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 years of age or older at time of consent Active Psoriatic Arthritis Clinically stable, plaque psoriasis involving more than 10% of the body surface area Evidence of skin conditions other than psoriasis that would interfere with skin examinations. Systemic antipsoriasis therapy or DMARD within 28 days of study drug initiation Prior exposure to any TNFinhibitor, including etanercept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Skin Disease</keyword>
	<keyword>Joint Disease</keyword>
</DOC>